Coronavirus company news summary – Moderna to seek early and conditional approval in the US and Europe for its Covid-19 vaccine – Regeneron and UPenn study intranasal administration of Covid-19 antibody cocktail

1 December 2020 (Last Updated December 1st, 2020 09:24)

1 December 2020 

Moderna announced high efficacy of its mRNA-1273 Covid-19 vaccine candidate in a Phase III study. Interim analysis data indicated a vaccine efficacy of 94.1% as there were 196 cases of Covid-19. As a result, Moderna have requested  emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) and conditional approval from the European Medicines Agency (EMA).

Novavax published an update on its Covid-19 vaccine clinical development programme. Its NVX‑CoV2373 vaccine is a stable, prefusion protein antigen developed from the genetic sequence of the Covid-19 spike  protein and adjuvanted with Novavax’s Matrix‑M™. Novavax has enrolled 15,000 participants in a Phase III trial in the UK, while a Phase IIb trial takes place in South Africa. The US and Mexico are also expected to see the start of Phase III trials in the coming weeks.

The Russian Direct Investment Fund (RDIF) and ChemRar Group announced the increase in production of Avifavir, a Russian drug for treating the SARS-Cov-2 virus. ChemRar has launched a full-scale, 24-hour production of the drug that has double the production levels in November to approximately 200,000 packs per month.

The University of Pennsylvania (UPenn) and Regeneron have collaborated to test if the latter’s casirivimab and imdevimab investigational antibody cocktail can fight Covid-19 when administered intranasally via adeno-associated viral vectors. The antibody cocktail is currently being investigated for treating and preventing the SARS-CoV-2 virus and has also been recently granted EUA by the FDA in certain high-risk patients suffering from mild to moderate symptoms.